Pharma BD Deal Intelligence
A generics deal that became foundational infrastructure — Lek is still a core Sandoz manufacturing hub more than two decades later.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Slovenia's attraction lay in its cost base — average annual salary under $35,000 vs $65,000 in Switzerland — a key advantage as European generics came under…
Over 65 per cent of shareholders in the Slovenian drugs company, Lek, have accepted a takeover offer... Novartis made a renewed bid worth $860 million, or…
Novartis bought Lek in 2002 for EUR 876 million (CHF 1.3 billion) — Slovenia's largest takeover to date — and has since invested more than EUR 1.3 billion in…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novartis, through its Sandoz division, acquired Lek Pharmaceuticals, Slovenia's largest drugmaker, for EUR 876M (CHF 1.3B) via a friendly public tender offer that reached 99.07% acceptance. The acquisition expanded Sandoz's global generics platform and completed in November 2002.
A generics deal that became foundational infrastructure — Lek is still a core Sandoz manufacturing hub more than two decades later.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Lek Pharmaceuticals d.d. (this deal) | 2002 | $876M | 88 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2002 deals · Novartis AG deals